Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease

Susan LaRusse, J. Scott Roberts, Theresa M. Marteau, Heather Katzen, Erin L. Linnenbringer, Melissa Barber, Peter Whitehouse, Kimberly Quaid, Tamsen Brown, Robert C. Green, Norman R. Relkin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: We examined how an Alzheimer disease (AD) family history assessment as compared to a risk assessment incorporating the absence of a disease-associated susceptibility allele affected risk perception among adult children with a family history of AD. Methods: The REVEAL study is a clinical trial in which adult children of patients with AD were randomized to receive a risk assessment based upon family history alone or family history plus apolipoprotein E (APOE) disclosure. In this analysis, two subsets of women were identified, each of whom received identical 29% lifetime risk estimates of developing AD. One group received a risk estimate that incorporated APOE ε4-negative genetic test results (Genotype Group, n = 30), whereas the other received a risk estimate based on family history and gender (Family History Group, n = 36). Six weeks after risk disclosure, we surveyed participants regarding the impact of the risk assessment on their perceptions of AD risk. Results: 73% of the Genotype Group judged their risk to be lower compared to 25% of the Family History Group (P < 0.0001). 67% of the Genotype Group reported lower anxiety about AD, versus 26% of the Family History Group (P < 0.01). 80% of the Genotype Group indicated that the risk information had a positive impact, versus 36% of the Family History Group (P < 0.001). The Genotype Group was less likely to believe that they would develop AD (13% vs. 36%, P < 0.05) and was more likely to report that the risk assessment removed uncertainty about their chances of developing AD (63% vs. 9%, P < 0.0001). Conclusions: These data suggest that risk estimates incorporating negative genetic test results affect perceptions of disease susceptibility more strongly than identical estimates based on family history alone.

Original languageEnglish (US)
Pages (from-to)48-53
Number of pages6
JournalGenetics in Medicine
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Genetic Testing
Genetic Predisposition to Disease
Alzheimer Disease
Genotype
Disease Susceptibility
Disclosure
Adult Children
Apolipoprotein E4
Apolipoproteins E
Uncertainty
Anxiety
Alleles
Clinical Trials

Keywords

  • Alzheimer disease
  • APOE
  • Genetic counseling
  • Genetic susceptibility testing
  • Risk perception

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

LaRusse, S., Roberts, J. S., Marteau, T. M., Katzen, H., Linnenbringer, E. L., Barber, M., ... Relkin, N. R. (2005). Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genetics in Medicine, 7(1), 48-53. https://doi.org/10.1097/01.GIM.0000151157.13716.6C

Genetic susceptibility testing versus family history-based risk assessment : Impact on perceived risk of Alzheimer disease. / LaRusse, Susan; Roberts, J. Scott; Marteau, Theresa M.; Katzen, Heather; Linnenbringer, Erin L.; Barber, Melissa; Whitehouse, Peter; Quaid, Kimberly; Brown, Tamsen; Green, Robert C.; Relkin, Norman R.

In: Genetics in Medicine, Vol. 7, No. 1, 01.01.2005, p. 48-53.

Research output: Contribution to journalArticle

LaRusse, S, Roberts, JS, Marteau, TM, Katzen, H, Linnenbringer, EL, Barber, M, Whitehouse, P, Quaid, K, Brown, T, Green, RC & Relkin, NR 2005, 'Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease', Genetics in Medicine, vol. 7, no. 1, pp. 48-53. https://doi.org/10.1097/01.GIM.0000151157.13716.6C
LaRusse, Susan ; Roberts, J. Scott ; Marteau, Theresa M. ; Katzen, Heather ; Linnenbringer, Erin L. ; Barber, Melissa ; Whitehouse, Peter ; Quaid, Kimberly ; Brown, Tamsen ; Green, Robert C. ; Relkin, Norman R. / Genetic susceptibility testing versus family history-based risk assessment : Impact on perceived risk of Alzheimer disease. In: Genetics in Medicine. 2005 ; Vol. 7, No. 1. pp. 48-53.
@article{4a8ec324f6c74911b3c1cad1b1fb7e05,
title = "Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease",
abstract = "Purpose: We examined how an Alzheimer disease (AD) family history assessment as compared to a risk assessment incorporating the absence of a disease-associated susceptibility allele affected risk perception among adult children with a family history of AD. Methods: The REVEAL study is a clinical trial in which adult children of patients with AD were randomized to receive a risk assessment based upon family history alone or family history plus apolipoprotein E (APOE) disclosure. In this analysis, two subsets of women were identified, each of whom received identical 29{\%} lifetime risk estimates of developing AD. One group received a risk estimate that incorporated APOE ε4-negative genetic test results (Genotype Group, n = 30), whereas the other received a risk estimate based on family history and gender (Family History Group, n = 36). Six weeks after risk disclosure, we surveyed participants regarding the impact of the risk assessment on their perceptions of AD risk. Results: 73{\%} of the Genotype Group judged their risk to be lower compared to 25{\%} of the Family History Group (P < 0.0001). 67{\%} of the Genotype Group reported lower anxiety about AD, versus 26{\%} of the Family History Group (P < 0.01). 80{\%} of the Genotype Group indicated that the risk information had a positive impact, versus 36{\%} of the Family History Group (P < 0.001). The Genotype Group was less likely to believe that they would develop AD (13{\%} vs. 36{\%}, P < 0.05) and was more likely to report that the risk assessment removed uncertainty about their chances of developing AD (63{\%} vs. 9{\%}, P < 0.0001). Conclusions: These data suggest that risk estimates incorporating negative genetic test results affect perceptions of disease susceptibility more strongly than identical estimates based on family history alone.",
keywords = "Alzheimer disease, APOE, Genetic counseling, Genetic susceptibility testing, Risk perception",
author = "Susan LaRusse and Roberts, {J. Scott} and Marteau, {Theresa M.} and Heather Katzen and Linnenbringer, {Erin L.} and Melissa Barber and Peter Whitehouse and Kimberly Quaid and Tamsen Brown and Green, {Robert C.} and Relkin, {Norman R.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.GIM.0000151157.13716.6C",
language = "English (US)",
volume = "7",
pages = "48--53",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Genetic susceptibility testing versus family history-based risk assessment

T2 - Impact on perceived risk of Alzheimer disease

AU - LaRusse, Susan

AU - Roberts, J. Scott

AU - Marteau, Theresa M.

AU - Katzen, Heather

AU - Linnenbringer, Erin L.

AU - Barber, Melissa

AU - Whitehouse, Peter

AU - Quaid, Kimberly

AU - Brown, Tamsen

AU - Green, Robert C.

AU - Relkin, Norman R.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: We examined how an Alzheimer disease (AD) family history assessment as compared to a risk assessment incorporating the absence of a disease-associated susceptibility allele affected risk perception among adult children with a family history of AD. Methods: The REVEAL study is a clinical trial in which adult children of patients with AD were randomized to receive a risk assessment based upon family history alone or family history plus apolipoprotein E (APOE) disclosure. In this analysis, two subsets of women were identified, each of whom received identical 29% lifetime risk estimates of developing AD. One group received a risk estimate that incorporated APOE ε4-negative genetic test results (Genotype Group, n = 30), whereas the other received a risk estimate based on family history and gender (Family History Group, n = 36). Six weeks after risk disclosure, we surveyed participants regarding the impact of the risk assessment on their perceptions of AD risk. Results: 73% of the Genotype Group judged their risk to be lower compared to 25% of the Family History Group (P < 0.0001). 67% of the Genotype Group reported lower anxiety about AD, versus 26% of the Family History Group (P < 0.01). 80% of the Genotype Group indicated that the risk information had a positive impact, versus 36% of the Family History Group (P < 0.001). The Genotype Group was less likely to believe that they would develop AD (13% vs. 36%, P < 0.05) and was more likely to report that the risk assessment removed uncertainty about their chances of developing AD (63% vs. 9%, P < 0.0001). Conclusions: These data suggest that risk estimates incorporating negative genetic test results affect perceptions of disease susceptibility more strongly than identical estimates based on family history alone.

AB - Purpose: We examined how an Alzheimer disease (AD) family history assessment as compared to a risk assessment incorporating the absence of a disease-associated susceptibility allele affected risk perception among adult children with a family history of AD. Methods: The REVEAL study is a clinical trial in which adult children of patients with AD were randomized to receive a risk assessment based upon family history alone or family history plus apolipoprotein E (APOE) disclosure. In this analysis, two subsets of women were identified, each of whom received identical 29% lifetime risk estimates of developing AD. One group received a risk estimate that incorporated APOE ε4-negative genetic test results (Genotype Group, n = 30), whereas the other received a risk estimate based on family history and gender (Family History Group, n = 36). Six weeks after risk disclosure, we surveyed participants regarding the impact of the risk assessment on their perceptions of AD risk. Results: 73% of the Genotype Group judged their risk to be lower compared to 25% of the Family History Group (P < 0.0001). 67% of the Genotype Group reported lower anxiety about AD, versus 26% of the Family History Group (P < 0.01). 80% of the Genotype Group indicated that the risk information had a positive impact, versus 36% of the Family History Group (P < 0.001). The Genotype Group was less likely to believe that they would develop AD (13% vs. 36%, P < 0.05) and was more likely to report that the risk assessment removed uncertainty about their chances of developing AD (63% vs. 9%, P < 0.0001). Conclusions: These data suggest that risk estimates incorporating negative genetic test results affect perceptions of disease susceptibility more strongly than identical estimates based on family history alone.

KW - Alzheimer disease

KW - APOE

KW - Genetic counseling

KW - Genetic susceptibility testing

KW - Risk perception

UR - http://www.scopus.com/inward/record.url?scp=19944429583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429583&partnerID=8YFLogxK

U2 - 10.1097/01.GIM.0000151157.13716.6C

DO - 10.1097/01.GIM.0000151157.13716.6C

M3 - Article

C2 - 15654228

AN - SCOPUS:19944429583

VL - 7

SP - 48

EP - 53

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 1

ER -